OLEMA
19 Apr 2022
Trial Summary
A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter, Study of OP-1250 in Adult Subjects with advanced and/or metastatic Hormone Receptor (HR)-positive, HER2-negative breast cancer
Acronym:
OLEMA
ACTRN/NCT /ethics:
NCT04505826
Scientific title:
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Sponsor / Cooperative group:
Olema Pharmaceuticals, Inc.
Trial & Patient Characteristics
| Cancer Type | Breast |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I; Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2020-08-13 |
| Anticipated End Date | 2023-12-01 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | Dr Meena Okera |
| Recruitment Status | Recruiting |